| NCT ID | NCT07690189 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | TeneoSeven, Inc. |
| Condition | Relapsed/Refractory Ovarian Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-06-29 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 90 participants in total. It began in 2026-06-29 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible. * Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy). * Are able to understand the study requirements and are willing to provide written informed consent * Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential Exclusion Criteria: * Have another active cancer that could interfere with assessment of this study treatment * Have received another investigational drug or certain cancer treatments within a recent period before starting this study * Are pregnant or breastfeeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07690189 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Relapsed/Refractory Ovarian Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07690189 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07690189 currently recruiting?
Yes, NCT07690189 is actively recruiting participants. Contact the research team at clinicaltrial@92biotech.com for enrollment information.
Where is the NCT07690189 trial being conducted?
This trial is being conducted at Birmingham, United States, Omaha, United States, Lake Success, United States, Fort Worth, United States.
Who is sponsoring the NCT07690189 clinical trial?
NCT07690189 is sponsored by TeneoSeven, Inc.. The trial plans to enroll 90 participants.